Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials

BMJ (Online)

Volumn 351, Issue , 2015, Pages

  Storebø, Ole Jakob ^a,b,c   Krogh, Helle B ^a,b   Ramstad, Erica ^a,b   Moreira Maia, Carlos R ^d   Holmskov, Mathilde ^a   Skoog, Maria ^e   Nilausen, Trine Danvad ^a   Magnusson, Frederik L ^a   Zwi, Morris ^f   Gillies, Donna ^g   Rosendal, Susanne ^h   Groth, Camilla ⁱ   Rasmussen, Kirsten Buch ^a   Gauci, Dorothy ^j   Kirubakaran, Richard ^k   Forsbøl, Bente ^b   Simonsen, Erik ^a,l   Gluud, Christian ^e  

^a Psychiatric Research Unit   (Denmark)

^b Child and Adolescent Psychiatric Department   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^e University of Copenhagen   (Denmark)

^f WHITTINGTON HOSPITAL NHS TRUST   (United Kingdom)

^g WESTERN SYDNEY LOCAL HEALTH DISTRICT   (Australia)

^h Psychiatric Centre North Zealand   (Denmark)

ⁱ GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^j DEPARTMENT OF HEALTH   (Malta)

^k CHRISTIAN MEDICAL COLLEGE   (India)

^l UNIVERSITY OF COPENHAGEN   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE; PLACEBO; CENTRAL STIMULANT AGENT;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; BONE DISEASE; CHILD; COCHRANE LIBRARY; DATA BASE; DECREASED APPETITE; DRUG MEGADOSE; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOPATHOLOGY; INFORMATION RETRIEVAL; ISCHEMIA; LOW DRUG DOSE; META ANALYSIS; MUSCLE DISEASE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PARALLEL DESIGN; PRIORITY JOURNAL; QUALITY CONTROL; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; SEQUENTIAL ANALYSIS; SLEEP DISORDER; SYMPTOM; TEACHER; TREATMENT DURATION; URINARY TRACT DISEASE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG ADMINISTRATION; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; HUMANS; METHYLPHENIDATE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84952683747     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h5203     Document Type: Article

References (71)

1. Scahill L, Schwab-Stone M. Epidemiology of ADHD in school-age children. Child Adolesc Psychiatr Clin N Am 2000;9:541-55.
2. Polanczyk GV, Salum GA, Sugaya LS, Caye A, Rohde LA. Annual research review: a meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. J Child Psychol Psychiatry 2015;56:345-65.
3. Schmidt S, Petermann F. Developmental psychopathology: Attention Deficit Hyperactivity Disorder (ADHD). BMC Psychiatry 2009;9:58.
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. APA; 2013.
5. World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. WHO; 1992.
6. Kadesjö B. ADHD hos barn och vuxna [ADHD in children and adults]. Socialstyrelsen; 2002.
7. National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. (Clinical guideline CG72.) 2008. www.nice.org.uk/guidance/cg72.
8. Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 2009;48:884-93.
9. Charach A, Yeung E, Climans T, Lillie E. Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses. J Am Acad Child Adolesc Psychiatry 2011;50:9-21.
10. Charach A, Carson P, Fox S, Ali MU, Beckett J, Lim CG. Interventions for preschool children at high risk for ADHD: a comparative effectiveness review. Pediatrics 2013;131:e1584-e1604.
11. Faraone SV, Biederman J, Roe C. Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis. J Clin Psychopharmacol 2002;22:468-73.
12. Faraone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the efficacy of medications for ADHD using meta-analysis. Med Gen Med 2006;8:4.
13. Faraone SV. Using Meta-analysis to compare the efficacy of medications for attention-deficit/hyperactivity disorder in youths. PT2009;34:678-94.
14. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 2010;71:754-63.
15. Hanwella R, Senanayake M, De Silva V. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. BMC Psychiatry 2011;11:176.
16. Kambeitz J, Romanos M, Ettinger U. Meta-analysis of the association between dopamine transporter genotype and response to methylphenidate treatment in ADHD. Pharmacogenomics J 2014;14:77-84.
17. King S, Griffin S, Hodges Z, et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technol Assess 2006;10:iii-146.
18. Maia CR, Cortese S, Caye A, et al. Long-term efficacy of methylphenidate immediate-release for the treatment of childhood ADHD: a systematic review and meta-analysis. J Atten Disord 2014; published online 10 Dec.
19. Punja S, Zorzela L, Hartling L, Urichuk L, Vohra S. Long-acting versus short-acting methylphenidate for paediatric ADHD: a systematic review and meta-analysis of comparative efficacy. BMJ Open 2013;3:e002312.
20. Reichow B, Volkmar FR, Bloch MH. Systematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit/hyperactivity disorder in children with pervasive developmental disorders. J Autism Dev Disord 2013;43:2435-41.
21. Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A metaanalysis. CMAJ 2001;165:1475-88.
22. Van Der Oord S, Prins PJ, Oosterlaan J, Emmelkamp PM. Efficacy of methylphenidate, psychosocial treatments and their combination in school-aged children with ADHD: a meta-analysis. Clin Psychol Rev 2008;28:783-800.
23. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. www.cochranehandbook.org.
24. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
25. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
26. Storebø O, Ramstad E, Krogh H, et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev 2015 (In press).
27. Storebø O, Pedersen N, Krogh H, et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents-assessment of harms in observational studies. Cochrane Database Syst Rev 2015; (In press).
28. Storebø OJ, Rosendal S, Skoog M, et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents [Protocol]. Cochrane Database Syst Rev 2012;5:CD009885.
29. ICH Expert Working Group. ICH harmonized tripartite guideline: guideline for good clinical practice E6 (R1) 1996. http://bit.ly/1B0jeJg.
30. Zhang S, Faries DE, Vowles M, Michelson D. ADHD Rating Scale IV: psychometric properties from a multinational study as a clinicianadministered instrument. Int J Methods Psychiatr Res 2005;14:186-201.
31. Rentz AM, Matza LS, Secnik K, Swensen A, Revicki DA. Psychometric validation of the child health questionnaire (CHQ) in a sample of children and adolescents with attention-deficit/hyperactivity disorder. Qual Life Res 2005;14:719-34.
32. Curtin F, Elbourne D, Altman DG. Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carry-over. Stat Med 2002;21:2161-73.
33. Hartman CA, Rhee SH, Willcutt EG, Pennington B. Modeling Rater Disagreement for ADHD: Are Parents or Teachers Biased? J Abnorm Child Psychol 2007;35:536-42.
34. Carlson GA, Dunn D, Kelsey D, et al. A pilot study for augmenting atomoxetine with methylphenidate: safety of concomitant therapy in children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health 2007;1:10.
35. Findling RL, Short EJ, McNamara NK, et al. Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46:1445-53.
36. Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008;165:721-30.
37. Palumbo DR, Sallee FR, Pelham WE, Bukstein OG, Daviss WB, McDermott MP. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry 2008;47:180-8.
38. Tucker JD, Suter W, Petibone DM, et al. Cytogenetic assessment of methylphenidate treatment in pediatric patients treated for attention deficit hyperactivity disorder. Mutat Res 2009;677:53-8.
39. Oesterheld JR, Kofoed L, Tervo R, Fogas B, Wilson A, Fiechtner H. Effectiveness of methylphenidate in Native American children with fetal alcohol syndrome and attention deficit/hyperactivity disorder: a controlled pilot study. J Child Adolesc Psychopharmacol 1998;8:39-48.
40. Pearson DA, Santos CW, Aman MG, et al. Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms. J Child Adolesc Psychopharmacol 2013;23:337-51.
41. Smith BH, Pelham WE, Evans S, et al. Dosage effects of methylphenidate on the social behavior of adolescents diagnosed with attention-deficit hyperactivity disorder. Exp Clin Psychopharmacol 1998;6:187-204.
42. Taylor E, Schachar R, Thorley G, Wieselberg HM, Everitt B, Rutter M. Which boys respond to stimulant medication? A controlled trial of methylphenidate in boys with disruptive behaviour. Psychol Med 1987;17:121-43.
43. Green T, Weinberger R, Diamond A, et al. The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardiofacial syndrome. J Child Adolesc Psychopharmacol 2011;21:589-95.
44. Szobot CM, Rohde LA, Katz B, et al. A randomized crossover clinical study showing that methylphenidate-SODAS improves attention-deficit/hyperactivity disorder symptoms in adolescents with substance use disorder. Braz J Med Biol Res 2008;41:250-7.
45. Roberts I, Ker K, Edwards P, Beecher D, Manno D, Sydenham E. The knowledge system underpinning healthcare is not fit for purpose and must change. BMJ 2015;350:h2463.
46. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 2008;61:64-75.
47. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol 2008;61:763-9.
48. Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analysis may be inconclusive-trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analysis. Int J Epidemiol 2009;38:287-98.
49. Thorlund K, Devereaux PJ, Wetterslev J, et al. Can trial sequential monitoring boundaries reduce spurious inferences from metaanalysis? Int J Epidemiol 2009;38:276-86.
50. Copenhagen Trial Unit. TSA trial sequential analysis. 0.9 Beta. [Computer program]. Copenhagen Trial Unit 2011. http://ctu.dk/tsa/downloads.aspx.
51. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Med Res Methodol 2009;9:86.
52. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001;135:982-9.
53. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev 2012;12:MR000033.
54. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analysis? Lancet 1998;352:609-13.
55. Savovic J, Jones HE, Altman DG, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med 2012;157:429-38.
56. Savovic J, Jones H, Altman D, et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technol Assess 2012;16:1-82.
57. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
58. Wood L, Egger M, Gluud LL, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336:601-5.
59. Gluud C, Nikolova D, Klingenberg SL. Cochrane Hepato-Biliary About the Cochrane Collaboration (Cochrane Review Groups (CRGs). Cochrane Rev Groups 2015;1 (Art. No: LIVER). www.cochranelibrary.com/about/cochrane-review-groups.html.
60. Andrews J, Guyatt G, Oxman AD, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 2013;66:719-25.
61. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for Trial Sequential Analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research. Copenhagen, Denmark 2011;1. www.ctu.dk/tsa.
62. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med 2009;3:e123-e130.
63. Martinez-Raga J, Knecht C, Szerman N, Martinez MI. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder. CNS Drugs 2013;27:15-30.
64. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev 2012;12:MR000033.
65. Schroll JB, Bero L, Gotzsche PC. Searching for unpublished data for Cochrane reviews: cross sectional study. BMJ 2013;346:f2231.
66. Murray DW, Kollins SH, Hardy KK, et al. Parent versus teacher ratings of attention-deficit/hyperactivity disorder symptoms in the preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol 2007;17:605-19.
67. Lavigne JV, Dulcan MK, LeBailly SA, Binns HJ. Can parent reports serve as a proxy for teacher ratings in medication management of attention-deficit hyperactivity disorder? J Dev Behav Pediatri 2012;33:336-42.
68. Caye A, Machado JD, Rohde LA. Evaluating parental disagreement in ADHD diagnosis: can we rely on a single report from home? J Atten Disord 2013; published online 4 Oct.
69. Efstratopoulou M, Simons J, Janssen R. Concordance among physical educators', teachers', and parents' perceptions of attention problems in children. J Atten Disord 2013;17:437-43.
70. Epstein T, Patsopoulos NA, Weiser M. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 2014;9:CD005041.
71. Storebø O, Gluud C. Criticism to "Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults". Email to: T Epstein via Wiley Online Feedback form, 12 May 2015.